STOCK TITAN
  1. Home
  2. News
  3. ONVO

Organovo Holdings Inc. - $ONVO STOCK NEWS

Welcome to our dedicated page for Organovo Holdings news (Ticker: $ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organovo Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organovo Holdings's position in the market.

News
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Rhea-AI Summary
Organovo announces positive Phase 2 results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH), showing reduction in liver fat content and strong safety and tolerability compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.66%
Tags
clinical trial
-
News
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
Rhea-AI Summary
Organovo Holdings, Inc. (ONVO) presented preclinical data on FXR314 at the Crohn’s and Colitis Congress, demonstrating its potential as a novel therapeutic approach for inflammatory bowel disease (IBD). The data showed significant improvement in epithelial barrier function and fibrotic activity in 3D models of human Crohn’s disease and ulcerative colitis. The company's focus on developing FXR314 for IBD treatment addresses the critical need for novel approaches beyond current pharmacological therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
-
News
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Rhea-AI Summary
Organovo Holdings, a clinical stage biotechnology company (NASDAQ: ONVO), announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress. The presentation will be made on January 26, 2024, by Dr. Fabrice Piu, Vice President, Research & Development. The company's current development program for FXR314 focuses on inflammatory bowel disease, highlighting the drug's differentiated mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
News
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Rhea-AI Summary
Organovo Holdings, Inc. (NASDAQ: ONVO) to Release Final Data from Phase 2a Trial of FXR314 in NASH Patients by April 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
clinical trial
-
News
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
Rhea-AI Summary
Organovo Holdings, Inc. (NASDAQ: ONVO) announces its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The company aims to establish a strong use case for FXR314 in patients and provide support for collaborations with major pharmaceutical companies offering IBD treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
-
News
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Rhea-AI Summary
Organovo Holdings, Inc. (NASDAQ: ONVO) intends to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The company aims to establish a strong use case for FXR314 in patients and provide support for collaborations with major pharmaceutical companies currently offering IBD treatments. The differentiated mechanism of action of FXR314 provides substantial promise that the drug’s impact will complement the biology of other successful drugs in the space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
none
News
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Organovo Holdings, Inc. to present corporate update at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
-
News
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Rhea-AI Summary
Organovo announces details about clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 shows positive promise in the treatment of ulcerative colitis and NASH. Company accelerates timeline for first clinical trials by approximately two years. Full Phase 2 data expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
clinical trial
-
News
Organovo Announces FXR Program
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
News
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
none
Stock ONVO logo
Organovo Holdings Inc.

Nasdaq:ONVO

ONVO Rankings

#5394 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ONVO Stock Data

10.37M
9.86M
3.05%
8.23%
1.61%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ONVO

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.